Patients demand guarantees that authorities will not make switches of biotherapeutic drugs solely for economic reasons and without considering the medical decision. This was expressed by the Uruguay Patients Alliance at the First National Biotechnology Forum. The main objective of this forum was to create a meeting place for the academic world, patients and health authorities in the field of biotechnology and innovation.
- Home
-
Generics
News
- Five Chinese companies join UN’s MPP for Covid-19 medicines
- South Korean companies to make generic Bridion and COVID-19 drugs
- Revlimid (lenalidomide) generics launch across Europe
- Cancer and diabetes generic treatments receive positive opinion from EMA’s CHMP
Research
- Re-evaluation of the use of generics, especially when treating conditions such as epilepsy
- Repurposing generic drugs can save time and money
- Availability of medicines and the sustainable development of the national health system in Russia
- Generic etoricoxib is equivalent to the reference drug
-
Biosimilars
News
- New adalimumab biosimilars prepare to launch in Canada, US and Europe
- FDA approves Amneal’s bevacizumab biosimilar
- Europe: positive opinion for Inpremzia and Truvelog Mix 30 and Stimufend authorized
- FDA approves Kashiv Biosciences’ filgrastim biosimilar
Research
- Innovent and Eli Lilly announce final results for sintilimab plus biosimilar bevacizumab injection
- Biosimilar adoption and prescribing in Japan: a physician opinion survey
- Totality of evidence supporting approval of Avsola in the treatment of IBD
- Survey results of biosimilars use among Spanish physicians and pharmacists
- MORE EDITORIAL SECTIONS
- Search
Post your comment